Pharmacogenetic study to predict the response to Tocilizumab in patients infected with SARS-CoV-2 (COVID-19)

First published 09/04/2020

Last updated 10/03/2021

EU PAS number:

EUPAS34653

Study

Planned

Download as PDF

Documents

Study protocol

No information provided.

Study results

No information provided.

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

Pharmacogenetic study to predict the response to Tocilizumab in patients infected with SARS-CoV-2 (COVID-19)

Secondary tabs

Share this page